Squaric acid dibutyl ester by Squarex Pharmaceutical for Herpes Labialis (Oral Herpes): Likelihood of Approval

Squaric acid dibutyl ester is under clinical development by Squarex Pharmaceutical and currently in Phase I for Herpes Labialis (Oral Herpes).

Genome-wide study finds link between CHD1L gene and HIV control

“We searched for human genetic variation that associates with spontaneous control of HIV and identified a novel region in the genome that is only variable

August 3, 2023

Ro’s weight loss business more than doubled in the last year. Now it’s trying to prove its program works

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

December 5, 2024

NIH launches $270 million anti-overdose research program for, and led by, Native Americans

Fatal drug overdoses shot up during the peak of Covid-19 in 2020. And as the dust settled on the pandemic, it quickly became clear that

August 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.